Logo

Atara Biotherapeutics, Inc.

ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors… read more

Healthcare

Biotechnology

8 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$13.74

Price

-0.65%

-$0.09

Market Cap

$96.496m

Small

Price/Earnings

19.6x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$188.667m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

$5.795m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.43

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$35.041m

$36.902m

Assets

$71.943m

Liabilities

$15.426m

Debt
Debt to Assets

41.8%

1.1x

Debt to EBITDA
Free Cash Flow

-$64.006m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases